NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger
Summary: NLS Pharmaceutics shared updates on its dual orexin receptor agonist (DOXA) platform, reporting promising preclinical findings for narcolepsy treatment, progress in financial restructuring, and plans for a merger with Kadimastem Ltd. The merger is expected to integrate NLS’ research into a broader pipeline of treatments for neurodegenerative and metabolic disorders while offering shareholders potential…